



Canada's Drug and  
Health Technology Agency

Updated CADTH Reimbursement  
Recommendations From a Streamlined Drug  
Class or Therapeutic Review

# Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes Mellitus

Streamlined Drug Class Review

March 7, 2024

On November 30, 2023, the Formulary Management Expert Committee (FMEC) deliberated on a streamlined drug class review for [sodium-glucose cotransporter-2 \(SGLT2\) inhibitors in type 2 diabetes mellitus](#).

## Rationale for Updates to CADTH Reimbursement Recommendations

Based on the overall evidence on efficacy, safety, and costs, FMEC voted (7 to 1) in favour of the following reimbursement recommendations:

### Recommendation 1

- SGLT2 inhibitors should be prioritized over sulfonylureas and dipeptidyl peptidase-4 (DPP-4) inhibitors in adults diagnosed with type 2 diabetes mellitus following inadequate control with metformin or a contraindication or intolerance to metformin.

### Recommendation 2

- SGLT2 inhibitors and glucagon-like peptide 1 (GLP-1) agonists both demonstrated clinical efficacy in the outcomes deemed important by FMEC. However, because of differences in cost, SGLT2 inhibitors should be prioritized over GLP-1 agonists in adults diagnosed with type 2 diabetes mellitus following inadequate control with metformin or a contraindication or intolerance to metformin unless the drug plan cost per patient of a GLP-1 agonist is no more than the least costly SGLT2 inhibitor.

As described in the [Procedures for CADTH Streamlined Drug Class Reviews](#), FMEC may provide updates to previous CADTH reimbursement recommendations, which can include amendments to the recommendation status, criteria, and/or conditions, as appropriate.

FMEC has updated the previous criteria and/or conditions set out by the Canadian Expert Drug Advisory Committee (CEDAC) or the Canadian Drug Expert Committee (CDEC) for therapeutics in type 2 diabetes mellitus based on the scope of the streamlined drug class review. Note that only relevant reviews with positive recommendations will be updated. Recommendations that were out of scope for the review (e.g., GLP-1 in combination with insulin) were not updated.

## Updates to CADTH Reimbursement Recommendations

The CADTH recommendations in this document now supersede the previously published recommendations for the relevant therapeutics.

Refer to [Table 1](#) (summary of revisions) and [Table 2](#) (summary of additions) for the updated CADTH reimbursement recommendations for these drugs, which includes the previous final recommendations (from CEDAC or CDEC) and updates by FMEC.

Table 1

## Summary of Revisions to Previous CADTH Reimbursement Recommendations

Generic name (brand name), project number	Date final recommendation (CDEC) issued	Final recommendation (CEDAC or CDEC)	Revisions to CEDAC or CDEC recommendation (by FMEC)
<b>SGLT2 inhibitors</b>			
<p><b>Canagliflozin (Invokana),</b> <a href="#">SR0370-000</a></p>	<p>January 15, 2015</p>	<p>CDEC recommends that canagliflozin be listed for the treatment of type 2 diabetes, if the following clinical criterion and conditions are met:</p> <ul style="list-style-type: none"> <li>• Added on to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea and for whom insulin is not an option</li> <li>• Drug plan costs for canagliflozin should not exceed the drug plan cost of dipeptidylpeptidase-4 (DPP-4) inhibitors</li> </ul>	<p>FMEC affirms that canagliflozin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus.</p> <p>The following amendment to conditions for reimbursement will now apply.</p> <p><b>Initiation</b></p> <p>For use in the case of contraindication or intolerance to metformin or added on to metformin for patients with inadequate glycemic control.</p> <p><b>Pricing</b></p> <p>The drug plan costs for canagliflozin should not exceed the least costly SGLT2 inhibitor used to treat type 2 diabetes mellitus.</p>
<p><b>Dapagliflozin (Forxiga),</b> <a href="#">SR0428-000</a></p>	<p>November 20, 2015</p>	<p>CDEC recommends that dapagliflozin be listed for use in patients with type 2 diabetes mellitus to improve glycemic control, if the clinical criteria and condition are met for any one of the following four scenarios:</p> <ul style="list-style-type: none"> <li>• Added on to metformin for patients: <ul style="list-style-type: none"> <li>◦ Who have inadequate glycemic control on metformin</li> <li>◦ Who have a contraindication or intolerance to a sulfonylurea</li> <li>◦ For whom insulin is not an option.</li> </ul> </li> <li>• Added on to a sulfonylurea for patients: <ul style="list-style-type: none"> <li>◦ Who have inadequate glycemic control on a sulfonylurea</li> <li>◦ Who have a contraindication or intolerance to metformin</li> <li>◦ For whom insulin is not an option.</li> </ul> </li> </ul>	<p>FMEC affirms that dapagliflozin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus.</p> <p>The following amendment to conditions for reimbursement will now apply.</p> <p><b>Initiation</b></p> <p>For use in the case of contraindication or intolerance to metformin or added on to metformin for patients with inadequate glycemic control.</p> <p><b>Pricing</b></p> <p>The drug plan costs for dapagliflozin should not exceed the least costly SGLT2 inhibitor used to treat type 2 diabetes mellitus.</p>

Generic name (brand name), project number	Date final recommendation (CDEC) issued	Final recommendation (CEDAC or CDEC)	Revisions to CEDAC or CDEC recommendation (by FMEC)
		<ul style="list-style-type: none"> <li>• Added on to insulin in combination with metformin for patients with inadequate glycemic control on insulin with metformin.</li> <li>• Added on to insulin without metformin for patients with the following:               <ul style="list-style-type: none"> <li>◦ Inadequate glycemic control on insulin</li> <li>◦ Contraindication or intolerance to metformin.</li> </ul> </li> </ul> <p>Drug plan cost of treatment with dapagliflozin should not exceed the drug plan cost of treatment with the least costly option from within the sodium-glucose cotransporter-2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor classes.</p>	
<p>Dapagliflozin-metformin hydrochloride (Xigduo), <a href="#">SR0468-000</a></p>	<p>July 20, 2016</p>	<p>CDEC recommends that dapagliflozin-metformin (Xigduo) be reimbursed for patients with type 2 diabetes mellitus if the following criterion and condition are met:</p> <ul style="list-style-type: none"> <li>• Patients who are already stabilized on therapy with metformin and dapagliflozin, to replace the individual component of dapagliflozin and metformin for those patients who:               <ul style="list-style-type: none"> <li>◦ Have inadequate glycemic control on metformin, a contraindication or intolerance to a sulfonylurea, and for whom insulin is not an option, or</li> <li>◦ Have inadequate glycemic control on metformin and insulin</li> </ul> </li> <li>• The drug plan cost for the dapagliflozin-metformin fixed-dose combination (FDC) should not exceed the combined cost of dapagliflozin and metformin administered separately.</li> </ul>	<p>FMEC affirms that dapagliflozin-metformin hydrochloride should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus.</p> <p><b>Initiation</b></p> <p>Dapagliflozin should be added on to metformin for patients with inadequate glycemic control.</p> <p><b>Pricing</b></p> <p>The drug plan costs for the dapagliflozin-metformin combination should not exceed the combined cost of the least costly SGLT2 inhibitor and metformin administered separately.</p>

Generic name (brand name), project number	Date final recommendation (CDEC) issued	Final recommendation (CEDAC or CDEC)	Revisions to CEDAC or CDEC recommendation (by FMEC)
Empagliflozin (Jardiance), <a href="#">SR0427-000</a>	October 15, 2015	<p>CDEC recommends that empagliflozin be listed for the treatment of type 2 diabetes, if the following clinical criterion and condition are met:</p> <ul style="list-style-type: none"> <li>• Added on to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea and for whom insulin is not an option</li> <li>• The drug plan cost of treatment with empagliflozin should not exceed the drug plan cost of treatment with the least costly option from within the sodium glucose cotransporter-2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor classes.</li> </ul>	<p>FMEC affirms that empagliflozin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus.</p> <p>The following amendment to conditions for reimbursement will now apply.</p> <p><b>Initiation</b></p> <p>For use in the case of contraindication or intolerance to metformin or added on to metformin for patients with inadequate glycemic control.</p> <p><b>Pricing</b></p> <p>The drug plan costs for empagliflozin should not exceed the least costly SGLT2 inhibitor used to treat type 2 diabetes mellitus.</p>
Empagliflozin-metformin (Synjardy), <a href="#">SR0489-000</a>	October 25, 2016	<p>CDEC recommends that empagliflozin and metformin hydrochloride (empagliflozin/metformin) fixed-dose combination (FDC) be reimbursed for patients with type 2 diabetes mellitus if the following clinical criteria and condition are met:</p> <ul style="list-style-type: none"> <li>• Patients who are eligible to receive metformin and empagliflozin based on participating drug plan reimbursement criteria, to replace the individual components of empagliflozin and metformin.</li> <li>• Drug plan costs for the empagliflozin/metformin FDC should not exceed the combined cost of empagliflozin and metformin administered separately.</li> </ul>	<p>FMEC affirms that empagliflozin-metformin hydrochloride should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus.</p> <p><b>Initiation</b></p> <p>Empagliflozin should be added on to metformin for patients with inadequate glycemic control.</p> <p><b>Pricing</b></p> <p>The drug plan costs for the empagliflozin-metformin combination should not exceed the combined cost of the least costly SGLT2 inhibitor and metformin administered separately.</p>

CDEC = Canadian Drug Expert Committee; CEDAC = Canadian Expert Drug Advisory Committee; FMEC = Formulary Management Expert Committee; SGLT2 = sodium-glucose cotransporter-2.

Table 2

## Summary of Additions to Previous CADTH Reimbursement Recommendations

Generic name (brand name)	Date final recommendation (CDEC) issued	Final recommendation (CEDAC or CDEC)	Addition(s) to CEDAC or CDEC recommendation (by FMEC)
<b>GLP-1 agonists</b>			
Semaglutide (Ozempic), <a href="#">SR0594-000</a>	May 15, 2019	<p>CDEC recommends that semaglutide be reimbursed for the treatment of type 2 diabetes mellitus (T2DM) to improve glycemic control, if the following conditions are met:</p> <ul style="list-style-type: none"> <li>• Adult patients diagnosed with T2DM with inadequate glycemic control.</li> <li>• In combination with metformin (MET) alone, when diet and exercise plus maximal tolerated dose of MET do not achieve adequate glycemic control.</li> <li>• Semaglutide should not be reimbursed for use as add-on therapy to MET and another antihyperglycemic drug.</li> <li>• Drug plan costs for semaglutide should not exceed the drug plan costs of the least costly currently reimbursed drug used when MET alone is insufficient to achieve glycemic control in the treatment of patients with T2DM.</li> </ul>	<p>FMEC affirms that semaglutide should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus.</p> <p>The following addition to conditions for reimbursement will now apply.</p> <p><b>Initiation</b></p> <p>The patient must have received a trial of an SGLT2 inhibitor unless the pricing condition is met.</p> <p><b>Pricing</b></p> <p>The drug plan costs for semaglutide should not exceed the least costly SGLT2 inhibitor used to treat type 2 diabetes mellitus.</p>
Semaglutide (Rybelsus), <a href="#">SR0637-000</a>	June 8, 2021	<p>CADTH recommends that Rybelsus should be reimbursed by public drug plans for the treatment of type 2 diabetes if certain conditions are met:</p> <ul style="list-style-type: none"> <li>• Rybelsus should only be reimbursed if it is used in addition to metformin or other antihyperglycemic agents and it does not cost more than glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.</li> </ul>	<p>FMEC affirms that semaglutide should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus.</p> <p>The following addition to conditions for reimbursement will now apply.</p> <p><b>Initiation</b></p> <p>The patient must have received a trial of an SGLT2 inhibitor unless the pricing condition is met.</p> <p><b>Pricing</b></p> <p>The drug plan costs for semaglutide should not exceed the least costly SGLT2 inhibitor used to treat type 2 diabetes mellitus.</p>

Generic name (brand name)	Date final recommendation (CDEC) issued	Final recommendation (CEDAC or CDEC)	Addition(s) to CEDAC or CDEC recommendation (by FMEC)
<b>Dulaglutide (Trulicity),</b> <a href="#">SR0462-000</a>	June 16, 2016	CDEC recommends that dulaglutide be reimbursed for the treatment of adults with type 2 diabetes mellitus in combination with metformin to improve glycemic control, if the following condition is met: <ul style="list-style-type: none"> <li>• Drug plan cost not to exceed that of the least costly pharmacotherapy reimbursed in combination with metformin.</li> </ul>	FMEC affirms that dulaglutide should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus. The following addition to conditions for reimbursement will now apply. <p><b>Initiation</b></p> The patient must have received a trial of an SGLT2 inhibitor unless the pricing condition is met. <p><b>Pricing</b></p> The drug plan costs for dulaglutide should not exceed the least costly SGLT2 inhibitor used to treat type 2 diabetes mellitus.
<b>DPP-4 inhibitors</b>			
<b>Linagliptin (Trajenta),</b> <a href="#">SR0244-000</a>	February 15, 2012	CDEC recommends that linagliptin be listed as a third drug added on to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea and for whom insulin is not an option.	FMEC affirms that linagliptin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus. The following addition to conditions for reimbursement will now apply. <p><b>Initiation</b></p> The patient must have received a trial of an SGLT2 inhibitor.
<b>Linagliptin- metformin (Jentadueto),</b> <a href="#">SR0306-000</a>	October 17, 2013	CDEC recommends that linagliptin/metformin be listed for patients if the following clinical criterion is met: <ul style="list-style-type: none"> <li>• Patients for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonylurea and linagliptin, to replace the individual components of linagliptin and metformin for these patients.</li> </ul>	FMEC affirms that linagliptin-metformin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus. The following addition to conditions for reimbursement will now apply. <p><b>Initiation</b></p> The patient must have received a trial of an SGLT2 inhibitor.

Generic name (brand name)	Date final recommendation (CDEC) issued	Final recommendation (CEDAC or CDEC)	Addition(s) to CEDAC or CDEC recommendation (by FMEC)
Saxagliptin (Onglyza), <a href="#">SR0329-000</a>	November 15, 2013	CDEC recommends that saxagliptin be listed if the following clinical criterion and condition are met: <ul style="list-style-type: none"> <li>• Added on to metformin and a sulfonyleurea for patients with inadequate glycemic control on metformin and a sulfonyleurea and for whom insulin is not an option.</li> <li>• Drug plan costs for saxagliptin should not exceed the cost of other dipeptidyl peptidase-4 (DPP-4) inhibitors</li> </ul>	FMEC affirms that saxagliptin should be reimbursed with criteria or conditions. The following addition to conditions for reimbursement will now apply. <p><b>Initiation</b></p> The patient must have received a trial of an SGLT2 inhibitor.
Saxagliptin-metformin (Komboglyze), <a href="#">SR0348-000</a>	June 20, 2014	CDEC recommends that saxagliptin/metformin be listed for patients if the following clinical criterion and condition are met: <ul style="list-style-type: none"> <li>• Patients for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonyleurea and saxagliptin, to replace the individual components of saxagliptin and metformin in these patients.</li> <li>• Drug plan costs for the saxagliptin/metformin fixed-dose combination (FDC) should not exceed the combined cost of saxagliptin and metformin administered separately.</li> </ul>	FMEC affirms that saxagliptin-metformin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus. The following addition to conditions for reimbursement will now apply. <p><b>Initiation</b></p> The patient must have received a trial of an SGLT2 inhibitor.
Sitagliptin (Januvia), <a href="#">SR0181-000</a>	June 23, 2010	CEDAC recommends that sitagliptin be listed as a third drug added on to metformin and a sulfonyleurea for patients with inadequate glycemic control on metformin and a sulfonyleurea and for whom insulin is not an option.	FMEC affirms that sitagliptin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus. The following addition to conditions for reimbursement will now apply. <p><b>Initiation</b></p> The patient must have received a trial of an SGLT2 inhibitor.
Sitagliptin phosphate monohydrate/metformin hydrochloride (Janumet), <a href="#">SR0182-000</a>	June 23, 2010	CEDAC recommends that sitagliptin/metformin (Janumet) be listed for use in patients for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonyleurea and sitagliptin, to replace the individual components of sitagliptin and metformin in these patients.	FMEC affirms that sitagliptin-metformin should be reimbursed with criteria or conditions for the treatment of type 2 diabetes mellitus. The following addition to conditions for reimbursement will now apply. <p><b>Initiation</b></p> The patient must have received a trial of an SGLT2 inhibitor.

CDEC = Canadian Drug Expert Committee; CEDAC = Canadian Expert Drug Advisory Committee; DPP-4 = dipeptidyl peptidase-4; FMEC = Formulary Management Expert Committee; GLP-1 = glucagon-like peptide 1; SGLT2 = sodium-glucose cotransporter-2.



The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Confidential information in this document may be redacted at the request of the sponsor in accordance with the CADTH Drug Reimbursement Review Confidentiality Guidelines.



Canada's Drug and  
Health Technology Agency

CADTH was established by Canada's federal, provincial, and territorial governments to be a trusted source of independent information and advice for the country's publicly funded health care systems. Health administrators and policy experts rely on CADTH to help inform their decisions about the life cycle management of drugs, devices, and services used to prevent, diagnose, and treat medical conditions.

CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

[cadth.ca](https://www.cadth.ca)

March 2024